Rollins Emily, director at Dolby Laboratories, sells $60,080 in stock

Emily Rollins, a director at Dolby Laboratories, Inc. (NASDAQ:DLB), sold 1,000 shares of Class A Common Stock on April 1, 2026, according to a Form 4 filing with the Securities and Exchange Commission. The shares were sold at a price of $60.08, for a total transaction value of $60,080. The stock currently trades at $61.79, and according to InvestingPro analysis, appears undervalued based on Fair Value calculations.

Following the transaction, Rollins directly owns 12,541 shares of Dolby Laboratories, Inc. , which includes 3,908 shares of Class A common stock underlying restricted stock units, which are subject to forfeiture until they vest.

The sale was disclosed in a Form 4 filing signed by Daniel Rodriguez as Attorney-in-Fact for Emily Rollins, and dated April 3, 2026. For deeper insights into Dolby’s financial health and exclusive ProTips, investors can access the comprehensive Pro Research Report available on InvestingPro.

In other recent news, Dolby Laboratories reported strong financial results for the first quarter of 2026. The company’s earnings per share (EPS) came in at $1.06, surpassing the expected $0.88, which represents a 20.45% positive surprise. Additionally, Dolby’s revenue reached $347 million, exceeding the forecast of $332.07 million. These results highlight Dolby’s ability to outperform market expectations. Analysts have taken note of these developments, with some firms likely to adjust their evaluations based on this performance. Dolby’s financial achievements could influence future analyst projections. Investors may find these developments noteworthy as they consider their positions. These recent results underscore Dolby’s current financial standing in the market.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.